Skip to Content

AP National Business

Merck has strong fourth quarter as COVID-19 treatment debuts

By TOM MURPHY AP Health Writer The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker’s COVID-19 treatment debuted with nearly $1 billion in sales. A 50% jump in sales for the Gardasil vaccine, which protects against cancer-causing human papilloma virus infections, also helped, Merck said Thursday. Overall, Merck earned $3.76 billion

Continue Reading
Skip to content